Download (pdf, 341 KB)

This information is for anyone with Crohn’s or Colitis who is considering, or has started, treatment with adalimumab. Adalimumab is also known as Humira or the biosimilars Amgevita, Hyrimoz, Imraldi, and Hulio.

It looks at:
• how the drug works
• what you can expect from treatment
• possible side effects
• stopping or changing treatment.

The information also aims to help you talk to your IBD team about the possible benefits and risks of adalimumab. And ask all the questions you need to make an informed decision about your treatment.